DNASE1L3 and metabolic dysfunction-associated steatotic liver disease: These findings broaden the potential functional scope of DNASE1L3 beyond its canonical nuclease activity and suggest that targeting cfDNA-PRR signaling, ER stress, ferroptotic pathways, or genomic stability may provide therapeutic opportunities for immune-metabolic subtypes of NAFLD.